{{Rsnum
|rsid=2246709
|Gene=CYP3A4
|Chromosome=7
|position=99768096
|Orientation=plus
|GMAF=0.3347
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CYP3A4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 51.3 | 41.6 | 7.1
| HCB | 32.1 | 51.8 | 16.1
| JPT | 43.4 | 47.8 | 8.8
| YRI | 45.6 | 42.2 | 12.2
| ASW | 43.9 | 45.6 | 10.5
| CHB | 32.1 | 51.8 | 16.1
| CHD | 35.8 | 45.0 | 19.3
| GIH | 46.5 | 44.6 | 8.9
| LWK | 48.2 | 39.1 | 12.7
| MEX | 22.4 | 65.5 | 12.1
| MKK | 59.4 | 38.1 | 2.6
| TSI | 55.9 | 38.2 | 5.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2246709
|Name_s=
|Gene_s=CYP3A4, CYP3A
|Feature=Intron, NA
|Evidence=PubMed ID:19907160
|Annotation=Protective allele: C; Phenotype: upon treatment with amlodipine, patients with C/C or C/T compared to a T/T genotype were twice as likely to reach a target mean arterial pressure (MAP) <107mmHG; study size: 145; study population: African-American men and women with early hypertensive nephrosclerosis ; significance value: hazards ratio 2.0; p-value 0.01
|Drugs=amlodipine
|Drug Classes=
|Diseases=Hypertension
|Curation Level=Curated
|PharmGKB Accession ID=PA165111358
}}

{{PMID Auto
|PMID=18825162
|Title=Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|OA=1
}}

{{PMID Auto
|PMID=22178823
|Title=[Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2246709
|overall_frequency_n=42
|overall_frequency_d=128
|overall_frequency=0.328125
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}